Drug research

UGN-102

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as UGN-102 (mitomycin) for intravesical solution

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT05243550	URGN	Phase 3	Active not recruiting	2023-04-26Actual
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)NCT05136898	URGN	Phase 3	Completed	2023-02-02Actual
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT04688931	URGN	Phase 3	Terminated	2023-03-17Actual

URGNActive not recruitingPrimary completion: 2023-04-26 · Actual

Trial details

URGNCompletedPrimary completion: 2023-02-02 · Actual

Trial details

URGNTerminatedPrimary completion: 2023-03-17 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.